Merck , known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus NS3/4A protease inhibitor, and MK-8742, an investigational HCV ... (more)
http://ift.tt/1i7tGEU
http://ift.tt/1i7tGEU
No comments:
Post a Comment